OGEN

Oragenics

0.19

-0.01-2.74%

After Hours: 0.1883 -0.00 -1.72%18:32 04/28 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.2000/0.1970

TODAY RANGE0.1870-0.2055

VOL313.18K

MARKET CAP4.11M

52 WEEK RANGE0.1617-3.430

AVG VOL (3M)4.95M

% TURNOVER1.46%

TURNOVER--

P/E (TTM)-0.1201

% RANGE9.39%

EPS(TTM)-1.5959

P/E(FORWARD)-0.5178

P/B-11.3373

BVPS-0.0169

DIVIDEND--

P/S15.70

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP3.57M

SHARES OUTSTANDING21.48M

NEXT EARNINGS05/13-05/19

FREE FLOAT18.62M

LOT SIZE1

EX-DIV DATE01/23/2023

News

Press Releases

Financial Reports

Profile

TipRanks·04/09 13:06
Oragenics announces HDEC submission for Phase II concussion trial
Benzinga·04/07 21:05
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga·04/02 21:05
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga·03/27 12:38
Oragenics Provides Q1 2025 Update Highlighting Strategic Progress In Concussion Treatment, Advancements In ONP-002, Partnership With BRAINBox Solutions, $5M Fundraising, And Key Regulatory And Clinical Milestones
TipRanks·03/06 14:35
Oragenics submits IB for Phase II clinical trial of ONP-002 in mTBI
TipRanks·02/25 14:03
Oragenics CMO to present at Emergencies in Medicine Conference
Dow Jones·02/24 13:30
Press Release: Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
TipRanks·02/11 13:41
Oragenics announces partnership with BRAINBox Solutions
TipRanks·02/07 16:15
Biotech Alert: Searches spiking for these stocks today
Benzinga·02/05 14:44
US Stocks Mixed; Walt Disney Posts Upbeat Earnings
Benzinga·02/05 12:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Dow Jones·02/04 21:16
*Oragenics Withdraws Filing for a Securities Offering
TipRanks·01/21 13:50
Oragenics appoints Huffman as interim CEO, provides shareholder update
Benzinga·01/21 13:35
Oragenics Provides Update On Strategic Progress Since $4M Capital Raise In September 2024, Including Phase II Prep And Device Enhancements; Appoints Janet Huffman As Interim CEO
Dow Jones·01/21 13:19
*Oragenics Before Tenure Oragenics, Huffman Was CFO for TRxADE HEALTH >OGEN

Same Industry

Name/Symbol

Change%

Price

Oragenics

OGEN

-2.74%

0.1916

Regeneron Pharmaceuticals

REGN

+1.36%

610.86

Entero Therapeutics

ENTO

+2.33%

0.3684

BIONTECH

BNTX

+1.94%

104.00

United Therapeutics Corp.

UTHR

+1.94%

297.04

Vertex Pharmaceuticals Inc

VRTX

+0.54%

496.49

Siga Technologie

SIGA

-2.31%

6.35

Moderna

MRNA

+0.88%

27.46

Charles Riv Labs Intl Inc

CRL

+0.37%

115.08

Medpace Holdings

MEDP

-0.12%

298.18

Talphera Inc

TLPH

-1.32%

0.4796

ICON PLC

ICLR

+0.03%

145.00

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-0.10%

150.13

MOLECULAR PARTNERS AG

MOLN

-2.84%

4.08

Arcturus Therape

ARCT

-0.70%

12.82

Gilead Sciences Inc

GILD

+3.07%

106.34

PRA Health

PRAH

165.21

Incyte Corp

INCY

+0.61%

59.52

Aptevo Therapeutics Inc

APVO

-9.31%

0.6120

Biospecifics

BSTC

+0.15%

88.53